GSK Receives FDA Accelerated Approval for Jemperli (dostarlimab-gxly) for Adult Patients with Mismatch Repair-Deficient (dMMR) Recurrent or Advanced Solid Tumors

17 August 2021 Second FDA approved indication for dostarlimab in 2021 GARNET study demonstrated objective response rate of 41.6% across dMMR solid tumors 95% of responders had a duration of response of≥6 months GlaxoSmithKline (GSK) plc...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news